Skip to main content
Clinical Trials/NCT00230685
NCT00230685
Recruiting
Not Applicable

Hammersmith Hospital Patients With Pulmonary Arteriovenous Malformations (PAVMs) and Hereditary Haemorrhagic Telangiectasia

Imperial College London1 site in 1 country2,000 target enrollmentStarted: January 2000Last updated:

Overview

Phase
Not Applicable
Status
Recruiting
Enrollment
2,000
Locations
1
Primary Endpoint
Venous thromboemboli (VTE)

Overview

Brief Summary

This observational study is for individuals with Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations that are reviewed at the Hammersmith Hospital, London.

Detailed Description

The Hammersmith Hospital provides a clinical service for patients with Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations that is unique in the United Kingdom. Measurements obtained as part of standard clinical practice that has evolved since 1985 allow us to assess whether particular groups of individuals that we see are more prone to recognised complications such as strokes, brain abscesses, pregnancy related complications or pulmonary hypertension. We hypothesise that certain clinical characteristics will predict the susceptibility of individuals to particular complications.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients attending Hammersmith Hospital

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Venous thromboemboli (VTE)

Time Frame: Prospective

VTE of any origin

Stroke

Time Frame: Prospective

Ischaemic stroke attributable to PAVMs

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials